Are Nootropics FDA Approved? The DSHEA Framework Explained
The short answer is no: the U.S. Food and Drug Administration does not approve dietary supplements — including nootropics — before they reach market. Under the Dietary Supplement Health and Education Act of 1994 (DSHEA), supplements are regulated as a category distinct from drugs. This page explains what that means in practice, what claims a supplement may legally make, and how to read the regulatory status of any nootropic product before purchasing.
How DSHEA actually works
DSHEA established that dietary supplements are regulated under the Federal Food, Drug, and Cosmetic Act as a category of food, not as drugs. Three consequences follow:
- No pre-market approval. Manufacturers are responsible for ensuring safety and accurate labelling before selling. The FDA can act after market entry if a product is shown to be unsafe or misbranded.
- No drug-like claims. Supplements may make "structure-function" claims describing how an ingredient affects the body, but cannot claim to diagnose, treat, cure, or prevent disease. Disease claims trigger drug classification under FDCA Section 201(g) and require full FDA drug approval.
- GMP requirements apply. Per 21 CFR Part 111, supplement manufacturing facilities must follow Current Good Manufacturing Practice. Facilities are subject to FDA inspection. "FDA-registered facility" means the facility is registered for inspection — it does not mean the product is FDA-approved.
Permitted vs prohibited claims under DSHEA
| Example claim | Status | Why |
|---|---|---|
| "Supports cognitive function" | ✓ DSHEA-permitted | Structure-function claim — describes how the ingredient affects normal body function. Allowed under DSHEA when followed by the FDA disclaimer. |
| "May help maintain focus and concentration" | ✓ DSHEA-permitted | Structure-function — "maintain" and "support" language is DSHEA-permitted. |
| "Promotes healthy memory function" | ✓ DSHEA-permitted | Structure-function — "healthy" qualifier signals normal-function support, not disease. |
| "Treats Alzheimer's disease" | ✗ Disease claim | Disease claim — implies treatment of a recognized medical condition. Triggers FDA drug classification under FDCA Section 201(g). |
| "Prevents dementia" | ✗ Disease claim | Disease claim — implies disease prevention. Drug-class language; would require FDA pre-market approval. |
| "Cures ADHD without prescription" | ✗ Disease claim | Disease + drug-replacement claim — multiple violations of DSHEA structure-function framework. |
The required FDA disclaimer
Any nootropic supplement making structure-function claims must include the following statement on its label and in advertising, per 21 CFR 101.93(c):
"These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease."
We require that disclaimer to appear (in some form) on every supplement we cover for the U.S. market. Products without it are flagged in our reviews.
Audit of our US catalog
We track 11 products in our U.S. catalog. Each is evaluated against DSHEA structure-function claim alignment, GMP-facility status (where verifiable), and NDI notification history (where applicable). Our editorial reviews flag products whose marketing language drifts into disease-claim territory.
Per-product DSHEA-claim audit is part of each review's 5-pillar transparency pillar; see the methodology page for the full framework.
Frequently asked questions
Does the FDA approve nootropic supplements?
No. The FDA does not approve dietary supplements before they reach market. Under the Dietary Supplement Health and Education Act of 1994 (DSHEA), supplements are regulated as food, not drugs. Manufacturers are responsible for ensuring their products are safe and properly labelled before selling. The FDA only takes action against unsafe or misbranded products after they enter the market.
What does "FDA registered" mean for a supplement?
A facility may be "FDA registered" — meaning the manufacturing facility is registered with the FDA and subject to GMP inspection under 21 CFR Part 111. This is not the same as FDA approval of the product itself. Many supplement marketing pages conflate the two; we flag this distinction in our reviews.
What is a "structure-function" claim?
A structure-function claim describes how a supplement ingredient affects the normal structure or function of the body, without claiming to diagnose, treat, cure, or prevent disease. Example: "supports cognitive function" is structure-function. "Treats Alzheimer's" is a disease claim and is not permitted on supplement labels without FDA drug approval.
What is the FDA disclaimer required on supplements?
Per DSHEA Section 6 and 21 CFR 101.93(c), products making structure-function claims must include the disclaimer: "These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease." This disclaimer must appear on labels and in advertising.
What is NDI notification?
New Dietary Ingredient (NDI) notification is a pre-market notification requirement for ingredients introduced to the U.S. supplement market after October 15, 1994. Manufacturers must notify the FDA at least 75 days before marketing the product, providing safety information. The FDA does not "approve" the NDI but may object if safety concerns are raised. Several common nootropic ingredients (citicoline, certain mushroom extracts, novel peptides) have NDI notifications on file.
Regulatory sources (6)expand
- RegulatoryDietary Supplement Health and Education Act of 1994 (DSHEA) — Public Law 103-417
- RegulatoryFDA — Dietary Supplements Overview
- Regulatory21 CFR Part 111 — Current Good Manufacturing Practice for dietary supplements
- Regulatory21 CFR 101.93 — Structure-function claim labelling requirements
- RegulatoryFDA — New Dietary Ingredient (NDI) Notification process
- EditorialThe Nootropic Lab — Methodology